Eledon Pharmaceuticals, Inc. Proceeds from Sale and Maturity of Debt Securities, Available-for-sale
Eledon Pharmaceuticals, Inc. (ELDN) reported Proceeds from Sale and Maturity of Debt Securities, Available-for-sale of $88.58 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities · last filed 2026-08-13
- Eledon Pharmaceuticals, Inc. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2026-06-30 was $39.50M, a 6.76% decline year-over-year.
- Eledon Pharmaceuticals, Inc. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2026-03-31 was $49.08M, a 37.31% increase year-over-year.
- Eledon Pharmaceuticals, Inc. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2025-12-31 was $48.76M, a 91.98% increase year-over-year.
- Eledon Pharmaceuticals, Inc. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2025-09-30 was $45.06M, a 111.37% increase year-over-year.
- Eledon Pharmaceuticals, Inc. proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2025 was $171.93M, a 100.34% increase from fiscal 2024.
- Eledon Pharmaceuticals, Inc. proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2024 was $85.82M, a 160.05% increase from fiscal 2023.
- Eledon Pharmaceuticals, Inc. proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2023 was $33.00M.
| Period end | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 3 month | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 6 month | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 9 month | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $39.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $88.58M 10-Q · filed 2026-08-13 | $137.34M derived: sum of 3 quarters · filed 2026-08-13 | $182.40M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $49.08M 10-Q · filed 2026-05-13 | $97.84M derived: sum of 2 quarters · filed 2026-05-13 | $142.90M derived: sum of 3 quarters · filed 2026-05-13 | $185.26M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $48.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $93.82M derived: sum of 2 quarters · filed 2026-03-19 | $136.18M derived: sum of 3 quarters · filed 2026-08-13 | $171.93M 10-K · filed 2026-03-19 |
| 2025-09-30 | $45.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $87.42M derived: sum of 2 quarters · filed 2026-08-13 | $123.16M 10-Q · filed 2025-11-14 | $148.56M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $42.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $78.10M 10-Q · filed 2026-08-13 | $103.50M derived: sum of 3 quarters · filed 2026-08-13 | $124.82M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $35.74M 10-Q · filed 2026-05-13 | $61.14M derived: sum of 2 quarters · filed 2026-05-13 | $82.46M derived: sum of 3 quarters · filed 2026-05-13 | $98.86M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $25.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $46.72M derived: sum of 2 quarters · filed 2026-03-19 | $63.12M derived: sum of 3 quarters · filed 2026-03-19 | $85.82M 10-K · filed 2026-03-19 |
| 2024-09-30 | $21.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $37.72M derived: sum of 2 quarters · filed 2025-11-14 | $60.42M 10-Q · filed 2025-11-14 | $88.42M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $16.40M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2025-08-14 | $39.10M 10-Q · filed 2025-08-14 | $67.10M derived: sum of 3 quarters · filed 2025-08-14 | |
| 2024-03-31 | $22.70M 10-Q/A · filed 2025-08-14 | $50.70M derived: sum of 2 quarters · filed 2025-08-14 | ||
| 2023-12-31 | $28.00M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-08-14 | $33.00M 10-K/A · filed 2025-08-14 | ||
| 2023-09-30 | $5.00M 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |